PDCD1 and non-small cell lung carcinoma: Evaluation of nivolumab efficacy in NSCLC PDX model in this enhanced ImmunoGraft® indicates that PD-1 blockade is feasible, and offers an opportunity to evaluate therapeutics targeting myeloid populations.